| Overview |  PrinterFriendlyVersion |
| Ex/Em(nm) | 498/520 |
| MW | N/A |
| CAS# | N/A |
| Solvent | DMSO |
| Storage | F/D/L |
| Category | EnzymeDetection PeptidasesandProteases |
| Related | MicroplateReaders BiochemicalAssays |
| Spectrum | AdvancedSpectrumViewer |
1.PrepareMMP-3containingBIOLOGicalsamplesasdesired.
2.Activatepro-MMP-3:
2.1 Make2mMAPMAworkingsolution(2X):Dilute1MAPMA(ComponentB)withAssayBuffer(ComponentC)at1:500togeta1mMAPMAworkingsolution(2X)
Note:APMAbelongstoorganicmercury.Handlewithcare!Disposeitaccordingtolocalregulations.
2.2 IncubatetheMMP-3with1mMAPMA:IncubatetheMMP-3containing-samplesorpurifiedMMP-3withequalvolumeof2mMAPMAworkingsolution(2X,fromStep2.1)at37oCfor24hours.ActivateMMP-3immediatelybeforetheexperiment.
Note1:Keepenzyme-containingsamplesonice.Avoidvigorouslyvortexingtheenzyme.Prolongedstorageoftheactivatedenzymewilldeactivatetheenzyme.
Note2:Forenzymeactivation,itispreferablyactivatedathigherproteinconcentration.Afteractivation,youmayfurtherdilutetheenzyme.
3.Prepareworkingsolutions:
3.1 MakeMMP-3Green™substrateworkingsolution:DiluteMMP-3Green™Substrate(ComponentA)withAssayBuffer(ComponentC)at1:100asshowninTable1.
Table1MMP-3Green™substrateworkingsolutionforone96-wellplate(100assays)
Components | Volume |
MMP-3Green™Substrate(ComponentA) | 50µL |
AssayBuffer(ComponentC) | 5mL |
Totalvolume | 5mL |
3.2 MakeMMP-3dilution:DiluteMMP-3toanappropriateconcentrationinAssayBuffer(ComponentC)ifpurifiedMMP-3isused.
Note:Pro-MMP-3needstobeactivatedbeforeuse(seeStep2.2).Avoidvigorousvortexingoftheenzyme.
3.3 Makeinhibitorsandcompoundsdilution:MakeanappropriateconcentrationofknownMMP-3inhibitorsandtestcompoundsdilutionsasdesiredifyouarescreeningMMP-3inhibitors.
4.Setuptheenzymaticreactionina96-wellmicroplateaccordingtoTable2andTable3:
Table2Layoutoftheappropriatecontrols(asdesired)andtestsamplesina96-wellmicroplate
SC | SC |
|
|
|
|
|
|
|
|
|
|
IC | IC |
|
|
|
|
|
|
|
|
|
|
VC | VC |
|
|
|
|
|
|
|
|
|
|
TC | TC |
|
|
|
|
|
|
|
|
|
|
TS | TS |
|
|
|
|
|
|
|
|
|
|
…. | …. |
|
|
|
|
|
|
|
|
|
|
…. | …. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:SC=SubstrateControl,IC=InhibitorControl,VC=VehicleControl,TC=TestCompoundControl,
TS=TestSamples.
Table3Reagentcompositionforeachwell
SubstrateControl | InhibitorControl | VehicleControl | TestCompoundControl* | TestSample |
Assaybuffer | MMP-3dilutionandknownMMP-3inhibitor | MMP-3dilutionandvehicleusedtodelivertestcompound | MMP-3containingassaybufferandtestcompound | MMP-3dilutionwithtestcompound |
Totalvolume:50μL | 50μL | 50μL | 50μL | 50μL |
Note1:*Somestronglyfluorescenttestcompoundsmayresultinfalse-positiveresults.
Note2:Makethetotalvolumeofallthecontrolsto50μLfora96-wellplateor20μLfora384-wellplatebyusingAssayBuffer(ComponentC).
5.Runtheenzymereaction:
5.1 Pre-incubatetheplateatadesiredtemperaturefortheenzymereaction(e.g.25oCor37oC)for10-15minutesifyouarescreeningMMP-3inhibitors.
5.2 Add50μL(96-well)or20μL(384-well)ofMMP-3Green™substrateworkingsolution(fromStep3.1)tothesampleandcontrolwellsoftheassayplate.Mixthereagentswell.
5.3 MonitorthefluorescenceintensitywithafluorescenceplatereaderatEx/Em=490/525nm.
ForkineticreADIng:Immediatelystartmeasuringfluorescenceintensityandcontinuouslyrecorddataevery5minutesfor30to60minutes.
Forend-pointreading:Incubatethereactionatroomtemperaturefor30to60minutes,keptfromlightifpossible.Mixthereagentswell,andthenmeasurethefluorescenceintensity.
| References&Citations |  CitationExplorer |
Connexin43UpregulationbyDioscinInhibitsMelanomaProgressionviaSuppressingMalignancyandInducingM1Polarization
Authors:YuKou,LiyanJi,HaojiaWang,WenshengWang,HongmingZheng,JuanZou,LinxinLiu,XiaoxiaoQi,ZhongqiuLiu,BiaoyanDu
Journal:InternationalJournalofCancer(2017)
DACT2,anepigeneticstimulator,exertsdualefficacyforcolorectalcancerpreventionandtreatment
Authors:LinlinLu,YingWang,RilanOu,QianFeng,LiyanJi,HongmingZheng,YueGuo,XiaoxiaoQi,Ah-NgTonyKong,ZhongqiuLiu
Journal:Pharmacologicalresearch(2017)
ProbingCellAdhesionProfileswithaMicroscaleAdhesiveChoiceAssay
Authors:HarshaKittur,AndyTay,AveryHua,MinYu,DinoDiCarlo
Journal:BiophysicalJournal(2017):1858--1867
InhibitionofBETbromodomainattenuatesangiotensinIIinducedaBDominalaorticaneurysminApoE-/-mice
Authors:QiongDuan,XiaoxiaoMao,ChaonanLiao,HaoyangZhou,ZelinSun,XuDeng,QiuningHu,JunQi,GuogangZhang,HeHuang
Journal:InternationalJournalofCardiology(2016):428--432
Tissueinhibitorofmetalloproteinase1influencesvascularadaptationstochronicalterationsinbloodflow
Authors:ErinRMandel,CassandraUchida,EmmanuelNwadozi,ArminMakki,TaraLHaas
Journal:JournalofCellularPhysiology(2016)
β-adrenoceptorsareupregulatedinhumanmelanomaandtheiractivationreleasespro-tumOrigeniccytokinesandmetalloproteasesinmelanomacelllines
Authors:SilviaMoretti,DanielaMassi,ValentinaFarini,GiannaBaroni,MatteoParri,StefaniaInnocenti,RobertoCecchi,PaolaChiarugi
Journal:LaboratoryInvestigation(2013):279--290
MatrixRemodelingMaintainsEmbryonicStemCellSelf-RenewalbyActivatingStat3
Authors:LaralynneMPrzybyla,ThoroldWTheunissen,RudolfJaenisch,JoelVoldman
Journal:StemCells(2013):1097--1106
IdentificationandfunctionalvalidationofCDH11,PCSK6andSH3GL3asnovelgliomainvasion-associatedcandidategenes
Authors:SDelic,NLottmann,KJetschke,GReifenberger,MarkusJRiemenschneider
Journal:Neuropathologyandappliedneurobiology(2012):201--212
EphA2inducesmetastaticgrowthregulatingamoeboidmotilityandclonogenicpotentialinprostatecarcinomacells
Authors:MariaLetiziaTaddei,MatteoParri,AdrianoAngelucci,FrancescaBianchini,ChiaraMarconi,ELISAGiannoni,GiovanniRaugei,MauroBologna,LidoCalorini,PaolaChiarugi
Journal:MolecularCancerResearch(2011):149--160
